Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06710067 · ClinicalTrials.gov registry record
Urine Metabolites in the Diagnosis of Disease
A clinical trial of Colorectal Cancer and Crohn Disease, sponsored by Luventix.
- Recruiting
- Registry status
- 1,250
- Enrollment target
- 4
- Study locations
NCT06710067 is a study of Colorectal Cancer and Crohn Disease that is actively recruiting participants, run by Luventix. The registered enrollment target is 1,250 participants, below the 1,508-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (17% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT06710067, a study of Colorectal Cancer and Crohn Disease, is actively recruiting participants, sponsored by Luventix.
- RECRUITING
- Registry status
- 1,250 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases. This research study intends to enroll participants across a range of demographics and GI disease states including colorectal cancer, small intestinal bacterial overgrowth (SIBO), Crohn\'s disease, and Celiac disease, collect urine samples and clinical data, and use artificial intelligence and machine learning to build disease-specific models which can identify and differentiate a participants' specific GI disease. The main questions it aims to answer are: 1. Does the platform identify a disease signal within each disease cohort, compared to normal controls? 2. How well does the test perform (e.g. sensitivity and specificity/false-positive rate)?
Conditions Studied
Study Locations (4)
California
- Unio Health Partners (Gastroenterology) - Encinitas
- Digestive Health Associates - Santa Monica
- Westside Gastro Care - Santa Monica
- Bass Medical Group (Gastroenterology) - Walnut Creek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2026-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06710067
The ClinicalTrials.gov registry entry for NCT06710067 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,508-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (17% lower). The listed sponsor is Luventix, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06710067 reports 4 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06710067 about?
NCT06710067 is a clinical study titled "Urine Metabolites in the Diagnosis of Disease". The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases. This research study intends to enroll participants across a range of demographics and GI disease states including co...
What is the current status of trial NCT06710067?
This trial is currently recruiting. The enrollment target is 1,250 participants. The study started on 2024-10-01. Estimated completion is 2026-09.
What conditions does trial NCT06710067 study?
This clinical trial studies the following conditions: Colorectal Cancer, Crohn Disease, Celiac Disease, Small Intestinal Bacterial Overgrowth Syndrome (SIBO).
Who is sponsoring clinical trial NCT06710067?
This trial is sponsored by Luventix, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06710067 being conducted?
This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.